Overview
Votrient contains Pazopanib, a targeted cancer therapy classified as a tyrosine kinase inhibitor (TKI). It is used primarily to treat advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma by blocking proteins that promote tumor growth and blood vessel formation.





